A practical reference on shelf life: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-29 and is reviewed periodically as new material appears.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
| Property | Value | Notes |
|---|---|---|
| Purity assay | RP-HPLC, UV 214 nm | Typical research grade 95 percent or higher |
| Mass confirmation | ESI-MS or MALDI-TOF | Compared with theoretical value |
| Main degradation route | Methionine oxidation | Sulfoxide formation in solution |
| Powder storage | -20 °C, desiccated | Amber vial, minimal headspace |
| Working solution | Sterile water or saline | Prepare fresh; avoid repeated thawing |
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Plants grown under UVB light are more resistant to insect herbivory compared with plants grown under filters that exclude the radiation. When tomato plants are exposed to a pulse of UVB radiation and then weakly wounded, PIs accumulate throughout the plant. By themselves, neither the radiation nor weak wounding is sufficient to induce systemic PI accumulation. Tomato cell cultures respond similarly, with systemin and UVB acting together to activate MAPKs. Short pulses of UVB also cause alkalisation of the culturing medium.
Febris (fever in Latin) is the goddess of fever in Roman mythology. People with fevers would visit her temples. Tertiana and Quartana are the goddesses of tertian and quartan fevers of malaria in Roman mythology. Jvarasura (fever-demon in Hindi) is the personification of fever and disease in Hindu and Buddhist mythology.
Deployment of such agents began to accelerate in late 2023 after OpenAI's "function-calling" API was made available, and especially after Anthropic's late 2024 introduction of Model Context Protocol (MCP), a standardised way for LLM agents to gain contextual awareness, and to act on the world by calling various external tools. The term "agentic" only began to be used with any frequency in 2024, popularised in part by researcher Andrew Ng.
== Interactions == Theoretical considerations suggest calcineurin inhibitors like ciclosporin and tacrolimus might interact with mifamurtide because of their effect on macrophages. High-dose NSAIDs block the mechanism of mifamurtide in vitro. Consequently, the combination of mifamurtide with these types of drugs is contraindicated. However, mifamurtide can be coadministered with low doses of NSAIDs. No evidence suggests mifamurtide interacts with the studied chemotherapeutics, or with the cytochrome P450 system.
It is also expected that thorium-232 should be able to undergo double beta decay, which would produce uranium-232, but this has not yet been observed experimentally. All isotopes from 232U to 236U inclusive have minor cluster decay branches (less than 10−10%), and all these bar 233U, in addition to 238U, have minor spontaneous fission branches; the greatest branching ratio for spontaneous fission is about 5×10−5% for 238U, or about one in every two million decays. The shorter-lived trace isotopes 237U and 239U exclusively undergo beta decay, with respective half-lives of 6.752 days and 23.45 minutes. In total, 28 isotopes of uranium have been identified, ranging in mass number from 214 to 242, with the exception of 220. Among the uranium isotopes not found in natural samples or nuclear fuel, the longest-lived is 230U, an alpha emitter with a half-life of 20.23 days. This isotope has been considered for use in targeted alpha-particle therapy (TAT). All other isotopes have half-lives shorter than one hour, except for 231U (half-life 4.2 days) and 240U (half-life 14.1 hours). The shortest-lived known isotope is 221U, with a half-life of 660 nanoseconds, and it is expected that the hitherto unknown 220U has an even shorter half-life. The proton-rich isotopes lighter than 232U primarily undergo alpha decay, except for 229U and 231U, which decay to protactinium isotopes via positron emission and electron capture, respectively; the neutron-rich 240U, 241U, and 242U undergo beta decay to form neptunium isotopes.
Sources: en.wikipedia.org
== Clinical significance == Mice with mutant carboxypeptidase E, Cpefat, display endocrine disorders like obesity and infertility. In some strains of mice, the fat mutation also causes hyperproinsulinemia in adult male mice, but this is not found in all strains of mice. The obesity and infertility in the Cpefat mice develop with age; young mice (<8 weeks of age) are fertile and have normal body weight. Peptide processing in Cpefat mice is impaired, with a large accumulation of peptides with C-terminal lysine and/or arginine extensions. Levels of the mature forms of peptides are generally reduced in these mice, but not eliminated. It is thought that a related enzyme (carboxypeptidase D) also contributes to neuropeptide processing and gives rise to the mature peptides in the Cpefat mice. Mutations in the CPE gene are not common within the human population, but have been identified. One patient with extreme obesity (Body Mass Index >50) was found to have a mutation that deleted nearly the entire CPE gene. This patient had intellectual disability (inability to read or write) and had abnormal glucose homeostasis, similar to mice lacking CPE activity. In obesity, high levels of circulating free fatty acids have been reported to cause a decrease in the amount of carboxypeptidase E protein in pancreatic beta-cells, leading to beta-cell dysfunction (hyperproinsulinemia) and increased beta-cell apoptosis (via an increase in ER stress).
In early 1954, he wrote the article "Cobalt 60 – Danger or Blessing for Mankind?", about the misuse of atomic energy, which was widely reprinted and transmitted in the radio in Germany, Norway, Austria, and Denmark, and in an English version worldwide via the BBC. The international reaction was encouraging. The following year he initiated and organised the Mainau Declaration of 1955, in which he and other international Nobel Prize-winners called attention to the dangers of atomic weapons and urgently warned the nations of the world against the use of "force as a final resort", and which was issued a week after the similar Russell-Einstein Manifesto. In 1956, Hahn repeated his appeal with the signature of 52 of his Nobel colleagues from all parts of the world. Hahn was also instrumental in and one of the authors of the Göttingen Manifesto of 13 April 1957, in which, together with 17 leading German atomic scientists, he protested against a proposed nuclear arming of the West German armed forces (Bundeswehr). This resulted in Hahn receiving an invitation to meet the Chancellor of Germany, Konrad Adenauer and other senior officials, including the Defense Minister, Franz Josef Strauss, and Generals Hans Speidel and Adolf Heusinger (who had both been generals in the Nazi era). The two generals argued that the Bundeswehr needed nuclear weapons, and Adenauer accepted their advice. A communiqué was drafted that said that the Federal Republic did not manufacture nuclear weapons, and would not ask its scientists to do so.
=== Fasciacyte === A fasciacyte is a type of biological cell that produces hyaluronan-rich extracellular matrix and modulates the gliding of muscle fasciae. Fasciacytes are fibroblast-like cells found in fasciae. They are round-shaped with rounder nuclei and have less elongated cellular processes when compared with fibroblasts. Fasciacytes are clustered along the upper and lower surfaces of a fascial layer. Fasciacytes produce hyaluronan, which regulates fascial gliding.
=== Aerobic Exercise === Aerobic exercise is also known as cardio because it is a form of cardiovascular conditioning. This includes exercises such as running, cycling, swimming and rowing. Athletes involved in aerobic exercise are typically looking to increase their endurance. These athletes are training their slow twitch muscle fibers to be better at taking in oxygen and getting it to their muscles. This is done by two mechanisms, glycolysis and aerobic respiration. Anaerobic glycolysis is also referred to as the "short term energy system", and is mostly used for high-intensity training, such as sprinting, and any sports which require quick bursts of speed. Slow twitch muscles are smaller in diameter and are slow to contract. These fibers don't store much glycogen, instead they use lipids and amino acids to generate energy. It has been shown that amino acids contributed around 3% of the total energy expenditure during endurance exercise. With a high concentration of myoglobin that stores oxygen, the slow twitch muscle fibers have plenty of oxygen to function properly. These factors help make slow twitch muscle fibers fatigue resistant so athletes can have endurance in their sport. There are many options for supplements that athletes can take to assist with endurance like glycerol and guarana.
In many high and middle income countries lower socioeconomic status is a strong predictor of smoking. Smoking rates in the United States have dropped by more than half from 1965 to 2016, falling from 42% to 15.5% of US adults. Australia is cutting their overall smoking consumption faster than most of the developed world, in part due to the landmark Plain Packaging Act, which standardized the appearance of cigarette packs. Other countries have considered similar measures. In New Zealand, a bill has been presented to Parliament which the government's associate health minister said "takes away the last means of promoting tobacco as a desirable product."
Sources: en.wikipedia.org
== Overview of Glyoxalase Pathway == The glyoxalase system includes glyoxalase I (GLO1), glyoxalase II (GLO2), and reduced glutathione (GSH). In bacteria, there is an additional enzyme known as glyoxalase III (GLO3), that can function in the absence of GSH. GLO3 has not been found in humans yet. The system pathway begins with methylglyoxal (MG), which is produced from non-enzymatic reactions with DHAP or G3P produced in glycolysis. Methylglyoxal is then converted into S-d-lactoylglutathione by enzyme GLO1 with a catalytic amount of GSH, of which is hydrolyzed into non-toxic D-lactate via GLO2, with liberation of GSH that can be consumed by GLO1 with a new molecule of MG. D-lactate ultimately goes on to be metabolized into pyruvate.
There are several GLP-1 receptor agonists approved in the EU to treat diabetes and weight management. Kayshild is the first GLP-1 medicine approved for this indication. In May 2026, the CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorization for the medicinal product Wegovy. The marketing authorization holder for this medicinal product is Novo Nordisk A/S. The CHMP adopted a new pharmaceutical form associated with a new route of administration, tablets for oral use, in four new strengths (1.5 mg, 4 mg, 9 mg and 25 mg).
==== Ribose aminooxazoline (RAO), a critical RNA precursor molecule ==== Ribose aminooxazoline (RAO) is a pentose aminooxazoline, first identified in 1970 as an important intermediate for ribonucleotide biosynthesis when it was shown to produce α-cytidine, a stereoisomer of the biologically-produced nucleoside β-cytidine. Over three decades later, the abiotic synthesis of RAO was achieved from the reaction of cyanamide and the simple 2- and 3-carbon compounds glycoaldehyde and glyceraldehyde, a demonstration of prebiotically feasible cyanosulfidic chemistry. Subsequent research additionally established an abiotic pathway from RAO to the pyrimidine ribonucleosides β-cytidine and β-uridine, revealing a plausible synthetic pathway to RNA monomers from simple chemical precursors that could have been available on the early Earth. Research into the synthesis of purine ribonucleosides is still underway, although a pathway from RAO to purine deoxyribonucleosides has been elucidated.
==== Physical performance ==== Caffeine is a proven ergogenic aid in humans. Caffeine improves athletic performance in aerobic (especially endurance sports) and anaerobic conditions. Moderate doses of caffeine (around 5 mg/kg) can improve sprint performance, cycling and running time trial performance, endurance (i.e., it delays the onset of muscle fatigue and central fatigue), and cycling power output. Caffeine increases basal metabolic rate in adults. Caffeine ingestion prior to aerobic exercise increases fat oxidation, particularly in persons with low physical fitness. Caffeine improves muscular strength and power, and may enhance muscular endurance. Caffeine also enhances performance on anaerobic tests. Caffeine consumption before constant load exercise is associated with reduced perceived exertion. While this effect is not present during exercise-to-exhaustion exercise, performance is significantly enhanced. This is congruent with caffeine reducing perceived exertion, because exercise-to-exhaustion should end at the same point of fatigue. Caffeine also improves power output and reduces time to completion in aerobic time trials, an effect positively (but not exclusively) associated with longer duration exercise.
The dentinal tubules contain the cytoplasmic extensions of odontoblasts that once formed the dentin and maintain it. The cell bodies of the odontoblasts are aligned along the inner aspect of dentin against a layer of predentin where they also form the peripheral boundary of the dental pulp Because of dentinal tubules, dentin has a degree of permeability, which can increase the sensation of pain and the rate of tooth decay. The strongest held theory of dentinal hypersensitivity suggests that it is due to changes in the dentinal fluid associated with the processes, possibly a type of hydrodynamic mechanism. Dentin is a bone-like matrix that is porous and yellow-hued material. It is made up, by weight, of 70–72% inorganic materials (mainly hydroxylapatite and some non-crystalline amorphous calcium phosphate), 20% organic materials (90% of which is collagen type 1 and the remaining 10% ground substance, which includes dentin-specific proteins), and 8–10% water (which is adsorbed on the surface of the minerals or between the crystals). Because it is less mineralized than enamel, it decays more rapidly and is subject to severe cavities if not properly treated, but due to its elastic properties, it is good support for enamel. Its flexibility prevents the brittle enamel fracturing during tooth preparation. In areas where both primary and secondary mineralization have occurred with complete crystalline fusion, these appear as lighter rounded areas on a stained section of dentin and are considered globular dentin.
Sources: en.wikipedia.org
Reversed-phase HPLC gives the main purity figure, most often with UV detection near 214 nanometres. Mass spectrometry then confirms the molecular mass. Together the two methods distinguish a correct sequence from a closely related impurity.
The main chemical risks are methionine oxidation and backbone hydrolysis in solution. Moisture and repeated temperature cycling accelerate both processes. Dry powder held cold and desiccated is considerably more stable than any reconstituted preparation.
It holds a medicine registration in Russia, where it has been used clinically for decades. In most other countries it is treated as a research chemical. That split explains the uneven distribution of clinical literature.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.